Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tedivax-Adult/ Td-Rix · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | dTPa vaccine |
| Group B | EXPERIMENTAL | Pa vaccine |
| Group C | ACTIVE_COMPARATOR | Tedivax-Adult™/ Td-Rix™ |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| GSK Biologicals' reduced-antigen-content acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| Tedivax-Adult™/ Td-Rix™ | BIOLOGICAL | Intramuscular, single dose or 2 doses (in the annex phase) |
Inclusion Criteria: * A male or female aged ≥18 years at the time of vaccination * Free of obvious health problems as established by medical history and clinical examination before entering into the study * Written informed consent obtained from the subject * If the subject is female, she must be o...
Tedivax-Adult/Td-Rix is a vaccine used for diphtheria, tetanus, and pertussis. It is being developed by GSK plc (GSK) and is currently in Phase 3 clinical development. The vaccine is intended for adults aged 18 years and older.
Tedivax-Adult/Td-Rix targets the bacterial toxins that cause diphtheria, tetanus, and pertussis (whooping cough). It is a reduced-antigen-content acellular pertussis vaccine combined with diphtheria and tetanus toxoids, designed to boost immunity in adults.
Tedivax-Adult/Td-Rix is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 3 clinical trials for the prevention of diphtheria, tetanus, and pertussis.
Tedivax-Adult/Td-Rix is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, with 116 participants enrolled.
Tedivax-Adult/Td-Rix has one completed Phase 3 trial registered as NCT01262924, titled "Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine." The trial enrolled 116 healthy adults aged 18 years and older and used an active-controlled design.
Yes, Tedivax-Adult/Td-Rix is also known as Td-Rix. The vaccine is being developed by GSK plc for the prevention of diphtheria, tetanus, and pertussis in adults, and it is currently in Phase 3 clinical development.